Evaluation of the HemoCue WBC DIFF in leukopenic patient samples

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Evaluation of the HemoCue WBC DIFF in leukopenic patient samples. / Kur, Dår K.; Agersnap, Niels; Holländer, Niels Henrik; Pedersen, Ole B.Vesterager; Friis-Hansen, Lennart.

In: International Journal of Laboratory Hematology, Vol. 42, No. 3, 06.2020, p. 256-262.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Kur, DK, Agersnap, N, Holländer, NH, Pedersen, OBV & Friis-Hansen, L 2020, 'Evaluation of the HemoCue WBC DIFF in leukopenic patient samples', International Journal of Laboratory Hematology, vol. 42, no. 3, pp. 256-262. https://doi.org/10.1111/ijlh.13158

APA

Kur, D. K., Agersnap, N., Holländer, N. H., Pedersen, O. B. V., & Friis-Hansen, L. (2020). Evaluation of the HemoCue WBC DIFF in leukopenic patient samples. International Journal of Laboratory Hematology, 42(3), 256-262. https://doi.org/10.1111/ijlh.13158

Vancouver

Kur DK, Agersnap N, Holländer NH, Pedersen OBV, Friis-Hansen L. Evaluation of the HemoCue WBC DIFF in leukopenic patient samples. International Journal of Laboratory Hematology. 2020 Jun;42(3):256-262. https://doi.org/10.1111/ijlh.13158

Author

Kur, Dår K. ; Agersnap, Niels ; Holländer, Niels Henrik ; Pedersen, Ole B.Vesterager ; Friis-Hansen, Lennart. / Evaluation of the HemoCue WBC DIFF in leukopenic patient samples. In: International Journal of Laboratory Hematology. 2020 ; Vol. 42, No. 3. pp. 256-262.

Bibtex

@article{ec8d05eefaa743a186790df193fc1665,
title = "Evaluation of the HemoCue WBC DIFF in leukopenic patient samples",
abstract = "Background: White blood cell (WBC) counts are used to monitor bone marrow function and to screen for infections. The HemoCue WBC DIFF Point-Of-Care (POC) instrument classifies WBCs through cell image recognition. To evaluate its suitability for monitoring cancer patients, we examined its performance in samples from patient with leukopenia and in samples containing nRBC. Methods: Sysmex samples with WBCs 0.05-3.40 × 109/L were examined on the HemoCue WBC DIFF, and the correlations between the instruments were assessed by Deming regression for total WBC, neutrophils, and lymphocytes. The theoretical CV% (CVt), calculated from number of cells counted by the HemoCue WBC DIFF, was used to determine the statistical error of the WBC counts. The interference of nRBC was also evaluated. Results: The counting variation was primarily the source of statistical error in the lower counts with an imprecision between 3.8–9.2% for total WBC (0.56–2.29 ×109/L), 8.7–14.3% for neutrophils (0.36–1.33 ×109/L) and 9.8–15.1% for lymphocytes (0.35–0.89 ×109/L). The correlation coefficient was between 0.658 and 0.986—poorest for lymphocytes. The total WBC count on the HemoCue WBC DIFF was significantly increased in nRBC samples due to lymphocyte count overestimation, and not by other WBCs. Conclusions: The HemoCue WBC DIFF provided reliable and accurate counts of total WBC, neutrophil, and lymphocyte in leukopenic samples. Until POC instruments that can perform an accurate complete blood count are available, the HemoCue WBC DIFF can be used to assist physicians in making decisions in situations of postchemotherapy leukopenia and neutropenia.",
keywords = "cancer patients, HemoCue WBC DIFF, leukopenia, neutropenia, nRBC, sysmex",
author = "Kur, {D{\aa}r K.} and Niels Agersnap and Holl{\"a}nder, {Niels Henrik} and Pedersen, {Ole B.Vesterager} and Lennart Friis-Hansen",
year = "2020",
month = jun,
doi = "10.1111/ijlh.13158",
language = "English",
volume = "42",
pages = "256--262",
journal = "Clinical and Laboratory Haematology",
issn = "1751-5521",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Evaluation of the HemoCue WBC DIFF in leukopenic patient samples

AU - Kur, Dår K.

AU - Agersnap, Niels

AU - Holländer, Niels Henrik

AU - Pedersen, Ole B.Vesterager

AU - Friis-Hansen, Lennart

PY - 2020/6

Y1 - 2020/6

N2 - Background: White blood cell (WBC) counts are used to monitor bone marrow function and to screen for infections. The HemoCue WBC DIFF Point-Of-Care (POC) instrument classifies WBCs through cell image recognition. To evaluate its suitability for monitoring cancer patients, we examined its performance in samples from patient with leukopenia and in samples containing nRBC. Methods: Sysmex samples with WBCs 0.05-3.40 × 109/L were examined on the HemoCue WBC DIFF, and the correlations between the instruments were assessed by Deming regression for total WBC, neutrophils, and lymphocytes. The theoretical CV% (CVt), calculated from number of cells counted by the HemoCue WBC DIFF, was used to determine the statistical error of the WBC counts. The interference of nRBC was also evaluated. Results: The counting variation was primarily the source of statistical error in the lower counts with an imprecision between 3.8–9.2% for total WBC (0.56–2.29 ×109/L), 8.7–14.3% for neutrophils (0.36–1.33 ×109/L) and 9.8–15.1% for lymphocytes (0.35–0.89 ×109/L). The correlation coefficient was between 0.658 and 0.986—poorest for lymphocytes. The total WBC count on the HemoCue WBC DIFF was significantly increased in nRBC samples due to lymphocyte count overestimation, and not by other WBCs. Conclusions: The HemoCue WBC DIFF provided reliable and accurate counts of total WBC, neutrophil, and lymphocyte in leukopenic samples. Until POC instruments that can perform an accurate complete blood count are available, the HemoCue WBC DIFF can be used to assist physicians in making decisions in situations of postchemotherapy leukopenia and neutropenia.

AB - Background: White blood cell (WBC) counts are used to monitor bone marrow function and to screen for infections. The HemoCue WBC DIFF Point-Of-Care (POC) instrument classifies WBCs through cell image recognition. To evaluate its suitability for monitoring cancer patients, we examined its performance in samples from patient with leukopenia and in samples containing nRBC. Methods: Sysmex samples with WBCs 0.05-3.40 × 109/L were examined on the HemoCue WBC DIFF, and the correlations between the instruments were assessed by Deming regression for total WBC, neutrophils, and lymphocytes. The theoretical CV% (CVt), calculated from number of cells counted by the HemoCue WBC DIFF, was used to determine the statistical error of the WBC counts. The interference of nRBC was also evaluated. Results: The counting variation was primarily the source of statistical error in the lower counts with an imprecision between 3.8–9.2% for total WBC (0.56–2.29 ×109/L), 8.7–14.3% for neutrophils (0.36–1.33 ×109/L) and 9.8–15.1% for lymphocytes (0.35–0.89 ×109/L). The correlation coefficient was between 0.658 and 0.986—poorest for lymphocytes. The total WBC count on the HemoCue WBC DIFF was significantly increased in nRBC samples due to lymphocyte count overestimation, and not by other WBCs. Conclusions: The HemoCue WBC DIFF provided reliable and accurate counts of total WBC, neutrophil, and lymphocyte in leukopenic samples. Until POC instruments that can perform an accurate complete blood count are available, the HemoCue WBC DIFF can be used to assist physicians in making decisions in situations of postchemotherapy leukopenia and neutropenia.

KW - cancer patients

KW - HemoCue WBC DIFF

KW - leukopenia

KW - neutropenia

KW - nRBC

KW - sysmex

U2 - 10.1111/ijlh.13158

DO - 10.1111/ijlh.13158

M3 - Journal article

C2 - 32039560

AN - SCOPUS:85079423002

VL - 42

SP - 256

EP - 262

JO - Clinical and Laboratory Haematology

JF - Clinical and Laboratory Haematology

SN - 1751-5521

IS - 3

ER -

ID: 242411831